Measuring Post-Buyback Performance: A Framework for Separating Alpha from Beta

A company announces a significant share buyback, and its stock price subsequently outperforms the broader market. It is a common narrative, but for the discerning trader, the story does not end there. The important question is: how much of that outperformance was due to the buyback itself (alpha), and how much was simply a reflection of the stock's sensitivity to the market (beta)? The ability to decompose post-buyback performance into these two components is essential for accurately evaluating the true impact of a repurchase program and for making informed trading decisions. This article presents a framework for doing just that.

The Challenge of Measuring True Impact

Measuring the true impact of a buyback is not as simple as comparing the stock's return to the return of the S&P 500. A stock's performance is influenced by a multitude of factors, including its industry, its size, its valuation, and its growth prospects. To isolate the impact of the buyback, we need to control for these other factors.

One of the most common ways to do this is to use a multi-factor model, such as the Fama-French three-factor model. This model explains a stock's return in terms of its sensitivity to three factors: the market factor (beta), the size factor (SMB, or small-minus-big), and the value factor (HML, or high-minus-low). By regressing a stock's returns against these three factors, we can determine how much of the return is explained by the factors and how much is unexplained. The unexplained portion is the alpha, and it is this alpha that we are interested in.

A Methodology for Creating a Peer Group and a Benchmark

To accurately measure the alpha generated by a buyback, we need to compare the stock's performance to a relevant benchmark. The S&P 500 is a good starting point, but it is not always the most appropriate benchmark. For example, if the company is a small-cap technology stock, it would be more appropriate to compare its performance to a small-cap technology index.

An even better approach is to create a custom peer group of companies that are similar to the company in question. This peer group should be composed of companies in the same industry, of a similar size, and with similar valuation and growth characteristics. By comparing the stock's performance to the performance of this peer group, we can get a much more accurate measure of the alpha generated by the buyback.

Using Regression Analysis to Isolate Alpha

Once we have a peer group and a benchmark, we can use regression analysis to isolate the alpha. The first step is to calculate the excess return of the stock and the excess return of the peer group. The excess return is the return of the stock or the peer group minus the return of the risk-free rate (e.g., the yield on a 3-month Treasury bill).

The next step is to regress the excess return of the stock against the excess return of the peer group. The output of this regression will give us two important numbers: the beta and the alpha. The beta is a measure of the stock's sensitivity to the peer group. A beta of 1.0 means that the stock is just as volatile as the peer group. A beta of 1.5 means that the stock is 50% more volatile than the peer group. The alpha is a measure of the stock's performance after controlling for its beta. A positive alpha means that the stock has outperformed the peer group, while a negative alpha means that it has underperformed.

Case Study: A Post-Mortem Analysis of a Major Buyback Program

Let's consider a hypothetical case study. In January 2023, a large-cap pharmaceutical company, PharmaCo, announced a $10 billion share buyback program. In the 12 months following the announcement, PharmaCo's stock returned 20%, while the S&P 500 returned 15%. On the surface, it looks like the buyback was a success. However, to be sure, we need to dig deeper.

First, we create a peer group of other large-cap pharmaceutical companies. We find that this peer group returned 18% over the same period. So, PharmaCo's stock outperformed its peers by 2%. This is a good start, but we still need to control for the stock's beta.

We regress PharmaCo's excess returns against the excess returns of the peer group. We find that the stock has a beta of 1.1 and an alpha of 0.5%. This means that after controlling for the stock's sensitivity to its peer group, the buyback generated an annualized alpha of 0.5%. This is a much more modest result than the initial 5% outperformance relative to the S&P 500, but it is also a much more accurate measure of the true impact of the buyback.

By using a rigorous framework for measuring post-buyback performance, traders can move beyond the simplistic narratives and gain a true understanding of the value created by these programs. This can lead to more informed trading decisions and a more profitable portfolio over the long run.